What Are the Final Stages of Leukemia Before Death?

The final stages of leukemia involve a cascading failure of normal body functions, driven primarily by the bone marrow’s inability to produce healthy blood cells. In practical terms, this means the body loses its defenses against infection, its ability to stop bleeding, and eventually the capacity to keep vital organs working. Infection has been the leading cause of death in acute leukemia patients for decades, followed by hemorrhage and organ failure. But the progression toward death is rarely a single, clean trajectory, and the specifics vary depending on the type of leukemia, the patient’s age, and the treatments they have received.

Why the Bone Marrow Stops Working

Leukemia is fundamentally a disease of the bone marrow, the spongy tissue inside bones where blood cells are made. As leukemia cells multiply, they displace the normal stem cells responsible for producing red blood cells, white blood cells, and platelets. Research has shown that the mechanism differs depending on the type of leukemia. In acute lymphoblastic leukemia (ALL), the leukemia cells physically crowd out normal stem cells by expanding and taking their space. In acute myeloid leukemia (AML), the bone marrow fails even before the leukemia cells have fully taken over, possibly through chemical signals released by the cancer cells that poison the environment for normal blood production.¹

The result is the same either way: the marrow eventually produces almost nothing useful. Without enough red blood cells, oxygen delivery to tissues drops. Without enough platelets, bleeding becomes difficult to control. And without enough functional white blood cells, the immune system essentially shuts down. This trio of problems, sometimes called pancytopenia, is the engine behind most of what happens in the final stages.

Infection as the Most Common Cause of Death

Across decades of research, infection remains the single biggest killer in advanced leukemia. A landmark study of 315 adults with acute leukemia found that infection, either alone or combined with other factors, caused death in about three out of four patients. Hemorrhage accounted for roughly a quarter, and organ failure about one in ten.² Those categories overlap in many cases, with patients dying from a combination of sepsis, bleeding, and organ shutdown rather than a single neat cause.

The vulnerability to infection comes from both the disease and its treatment. Chemotherapy, when it is still being given, destroys the remaining functional white blood cells along with the leukemia cells. The resulting state of very low white blood cell counts, called neutropenia, leaves the body almost defenseless. Bacteria, fungi, and viruses that a healthy immune system would handle easily can become rapidly fatal.³ In one study of AML patients receiving intensive chemotherapy, fever during neutropenia occurred during nearly all chemotherapy cycles, and about one in ten patients died from severe sepsis.⁴

When treatment has stopped working and the leukemia is progressing unchecked, the immune collapse becomes permanent rather than temporary. Patients in these final stages can develop infections from organisms already living in their own gut or on their skin. Research using advanced genetic analysis of bloodstream infections has confirmed that patients with the lowest white blood cell counts carry the highest levels of microbial DNA in their blood, meaning bacteria are circulating freely through the body with little resistance.⁵

Bleeding That Cannot Be Stopped

Platelets are the blood cells responsible for clotting, and leukemia progressively destroys the marrow’s ability to produce them. When platelet counts drop very low, bleeding can start spontaneously without any injury. In patients with advanced blood cancers followed at home, those with extremely low platelet counts had a much higher rate of hemorrhagic complications. Among nearly 470 patients who died, about 6% died directly from bleeding, most commonly from hemorrhages in the brain, the lungs, or the gastrointestinal tract.⁶

It is worth noting that while bleeding is a well-known threat, some research suggests overt fatal bleeding may be less common than many people assume. A study of AML patients in their final week of life found that no patient in the group died from overt hemorrhage. Infection and the leukemia itself were responsible instead.⁷ The discrepancy probably reflects the difference between populations: patients in hospital settings may receive platelet transfusions that prevent fatal bleeds, while those at home or in hospice may not have the same access. Bleeding that happens internally, particularly in the brain, can also be difficult to distinguish from other causes of rapid decline.

When Organs Begin to Fail

As the disease progresses, organs beyond the bone marrow start to break down, either from direct invasion by leukemia cells, from the side effects of the body’s collapse, or both.

Lungs

Breathing problems are among the most distressing symptoms in the final stages. Leukemia cells can directly infiltrate the lungs, causing a form of respiratory failure that looks similar to severe pneumonia on imaging. In a study of patients with acute monocytic leukemia who developed respiratory failure, most showed widespread infiltrates in both lungs, and two-thirds of those who needed mechanical ventilation died.⁸ Even when leukemia cells are not directly in the lungs, patients can develop fluid buildup around the lungs (pleural effusion) or bleeding into the lung tissue from low platelets.

Kidneys

The kidneys are vulnerable to a specific complication called tumor lysis syndrome, which occurs when a large number of leukemia cells die at once, releasing their contents into the bloodstream. The flood of cellular debris, including uric acid and potassium, can overwhelm the kidneys and cause acute kidney failure. This is considered a medical emergency.⁹ In one analysis of AML patients, kidney failure developed in the vast majority of those who experienced tumor lysis syndrome during treatment induction.¹⁰ In the final stages, when treatment is no longer being pursued, kidney failure may develop more gradually from the accumulated damage of the disease.

Brain and Nervous System

Leukemia cells can infiltrate the central nervous system, and this becomes more common as the disease advances. Autopsy studies have found that roughly four out of five patients with ALL had leukemia cells in the brain or spinal cord at death, and nearly half of AML patients did as well. Among chronic lymphocytic leukemia (CLL) patients, about half had central nervous system involvement at autopsy. Other findings at death, including hemorrhages and infarcts in the brain, were present in about a third of all leukemia patients studied.¹¹ In CLL, a mild, often asymptomatic infiltration of the brain is frequently noted in late-stage disease and can explain changes in mental status and cerebrospinal fluid abnormalities.¹²

For families, the neurological effects often manifest as increasing confusion, sleepiness, or difficulty communicating. These changes can be caused by leukemia cells in the brain, by bleeding in the brain from low platelets, by infection, or simply by the body’s general decline.

The Gut

The gastrointestinal tract is another target. The lining of the intestines is one of the most rapidly dividing tissues in the body, making it vulnerable both to leukemia infiltration and to chemotherapy damage. Severe intestinal inflammation, sometimes called neutropenic enterocolitis, can develop during periods of very low white blood cell counts, and the condition can be life-threatening on its own.¹³ In the final stages, loss of appetite and an inability to eat are near-universal.

What the Last Days Actually Look Like

A study examining the final week of life in AML patients found that the leukemia itself was the direct cause of death in about half of all cases. Infection and organ failure accounted for much of the rest. About three-quarters of patients had been transitioned to palliative-focused care during their last week. Around 30% of patients under age 80, however, were still receiving intensive chemotherapy aimed at remission when they died.⁷ That statistic reflects one of the persistent tensions in leukemia care: the disease can sometimes respond dramatically to treatment even at advanced stages, which makes it harder for doctors and patients to agree on when to stop trying.

A randomized trial comparing standard care to integrated palliative and oncology care for AML patients found that patients who received integrated palliative care were much more likely to have discussed their end-of-life preferences with their doctors and were less likely to receive chemotherapy in the last month of life. Despite this, rates of hospitalization during the final week remained high in both groups, with more than three-quarters of patients spending their last week in the hospital regardless of which approach they received.¹⁴

Chronic Leukemia in the Final Stages

Chronic leukemias, such as chronic myeloid leukemia (CML) and CLL, follow a different path than the acute forms, but the end stage can look remarkably similar. CML, for example, typically starts as a slow-moving disease that can be managed for years. But without effective treatment or when treatment stops working, CML transforms into what is called blast crisis, a phase that resembles acute leukemia and is generally not curable with chemotherapy alone.¹⁵ Once blast crisis occurs, the same problems that define the final stages of acute leukemia, including bone marrow failure, infections, and bleeding, take over.

CLL tends to progress more gradually. Many patients with CLL die of unrelated causes, having lived with the disease for years. But for those whose CLL becomes aggressive or transforms into a faster-growing lymphoma (a process known as Richter’s transformation), the final trajectory accelerates. As noted in the autopsy data above, even seemingly quiet CLL can be silently infiltrating the brain and other organs by the time of death.

How the End of Life Differs in Children

Children with leukemia who reach the terminal phase carry an exceptionally high symptom burden. A study of children with blood cancers admitted to pediatric palliative care found a median of 94 recorded symptoms within the first seven days. These children experienced more severe fatigue, weakness, loss of appetite, mouth sores, difficulty moving, and drowsiness compared to children with other terminal cancers. They also had more problems related to the blood system itself, including visible bruising and extreme paleness, as well as unstable body temperature from overwhelmed immune systems.¹⁶

Beyond the physical toll, children with terminal leukemia experience significant psychological suffering, including fear, anxiety, and sadness.¹⁷ Research also suggests that the number of situations calling for palliative intervention increases as death approaches, which means the final weeks tend to become progressively more difficult rather than leveling off.¹⁸

The Transfusion Problem and Hospice Access

One of the most frustrating aspects of end-of-life care for leukemia patients is a structural barrier that has nothing to do with the disease itself: most hospice programs in the United States do not provide blood transfusions. This creates a painful dilemma, because many leukemia patients in their final weeks depend on transfusions of red blood cells or platelets just to manage symptoms like severe fatigue and bleeding risk. Without transfusions, their quality of life can deteriorate rapidly, but accepting hospice often means giving them up.

Data from a large Medicare-linked study found that about one in five leukemia patients were transfusion-dependent in the period before death or hospice enrollment. Overall hospice use rose from about 35% in 2001 to nearly half by 2011, but the median time spent in hospice was just nine days. For transfusion-dependent patients, that dropped to six days, roughly half the length of stay seen in patients who did not need transfusions.¹⁹ The pattern suggests these patients are being referred to hospice very late, often only in the last few days of life, in part because the decision to stop transfusions feels like a turning point that is hard to accept.

The barriers go beyond transfusions. An unpredictable disease course makes it hard for doctors to identify the right moment for hospice referral. The close relationship between patients and their hematologists can make it emotionally difficult to initiate end-of-life conversations. And many patients and families misunderstand what hospice and palliative care actually offer, confusing comfort-focused care with giving up.²⁰ Experts in palliative hematology have argued that hospice programs should be able to provide transfusions for symptom control, and that patients should not have to choose between comfort measures and blood product support.²¹

Even when hospice transfer does happen, the level of medical care needed by leukemia patients during their final week tends to remain intensive compared to patients with solid tumors. Their symptoms are more complex, their need for interventions like transfusions and antibiotics is greater, and the line between aggressive treatment and comfort care is blurrier.²²

What Families Go Through

The experience of caring for someone dying of leukemia places enormous psychological strain on family members. The unpredictability of the disease, repeated cycles of hope and setback, and the physical demands of caregiving create a sustained state of stress, anxiety, and depression in caregivers.²³ Unlike cancers where the decline is relatively predictable, leukemia can shift suddenly from a period of relative stability to a life-threatening crisis, leaving families with little time to adjust emotionally.

Families often face difficult decisions about whether to continue treatment, when to pursue hospice, and how to balance the patient’s wishes against medical reality. The same prognostic uncertainty that makes it hard for doctors to identify the right moment for end-of-life conversations makes it equally hard for families to prepare. Programs designed specifically around caregiver needs, addressing practical questions and providing psychological support, have been shown to reduce caregiver distress. But access to such programs remains uneven, and many families navigate the final stages with limited guidance.

One of the things that makes leukemia’s end stage particularly disorienting for families is the medical intensity right up until the end. Many patients are still in the hospital, still receiving blood products, still being treated for infections, sometimes still receiving chemotherapy. The transition from “we are fighting this” to “we are keeping you comfortable” can happen over hours rather than weeks, and it does not always happen as a single clear moment. For some families, the shift comes only after the patient is too sick to participate in the conversation, which underscores why earlier palliative care involvement matters so much in blood cancers.²⁴